Biosplice Therapeutics was last valued at $12B (post-money). It comes from the $120M Series D of Apr 2021. The company is private, so there is no listed share price.
3 valuations. The latest, $12B post-money, was set by the Series D in Apr 2021.
A private valuation is the price agreed in one transaction. The Biosplice Therapeutics valuation of $12B is a post-money figure from the Series D dated 15 Apr 2021 — the whole company measured after the $120M raised in that round was already inside it. Subtract the round and the pre-money view of the same deal is $11.9B .
The valuation holds until the next priced round or secondary sale. A private company founded in 2008 with roughly 39 people has no daily price and no order book between rounds.
The closest biopharmaceutical — regenerative medicine / alternative pre-mrna splicing therapeutics peers are on the competitors page.
The routes section explains what is realistically available for a company at this stage.
No. Biosplice Therapeutics is a private company; its shares do not trade on a public exchange.
The last valuation is $12B.
Perpetual markets for stocks, gold, indices and pre-IPO names — settled on-chain, no wallet-to-exchange transfers.
